These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S; Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706 [TBL] [Abstract][Full Text] [Related]
3. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries. Bazargani YT; Ugurlu M; de Boer A; Leufkens HGM; Mantel-Teeuwisse AK BMC Cardiovasc Disord; 2018 Jun; 18(1):126. PubMed ID: 29940880 [TBL] [Abstract][Full Text] [Related]
4. Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries. Kishore SP; Vedanthan R; Fuster V J Am Coll Cardiol; 2011 May; 57(20):1980-7. PubMed ID: 21565635 [TBL] [Abstract][Full Text] [Related]
5. Associations between essential medicines and health outcomes for cardiovascular disease. Steiner L; Fraser S; Maraj D; Persaud N BMC Cardiovasc Disord; 2021 Mar; 21(1):151. PubMed ID: 33765933 [TBL] [Abstract][Full Text] [Related]
6. Rational use of medications: if Canada can't do it .. Califf RM CMAJ; 2009 Jul; 181(1-2):15-6. PubMed ID: 19581612 [No Abstract] [Full Text] [Related]
7. Trends in Cardiovascular Medicine Use in 65 Middle- and High-Income Countries. Yan VKC; Blais JE; Li X; Chui CSL; Wei L; Yan BP; Knapp MRJ; Siu CW; Wong ICK; Chan EW J Am Coll Cardiol; 2021 Feb; 77(7):1021-1023. PubMed ID: 33602460 [No Abstract] [Full Text] [Related]
8. Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians? Tu JV Can J Cardiol; 2007 Jul; 23(9):719-20. PubMed ID: 17622394 [No Abstract] [Full Text] [Related]
9. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics. Califf RM Am Heart J; 1999 May; 137(5):S35-7. PubMed ID: 10220593 [No Abstract] [Full Text] [Related]
10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear. Detsky AS Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597 [No Abstract] [Full Text] [Related]
11. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status. Maniadakis N; Kourlaba G; Shen J; Holtorf A BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440 [TBL] [Abstract][Full Text] [Related]
12. Forecasting the quantity and cost of medicines to treat non-communicable diseases in low- and middle-income countries: Applying knowledge on medicine use from developed countries. Khanal S; Veerman L; Nissen L; Hollingworth S Res Social Adm Pharm; 2017; 13(1):257-258. PubMed ID: 27591096 [No Abstract] [Full Text] [Related]
13. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Attaei MW; Khatib R; McKee M; Lear S; Dagenais G; Igumbor EU; AlHabib KF; Kaur M; Kruger L; Teo K; Lanas F; Yusoff K; Oguz A; Gupta R; Yusufali AM; Bahonar A; Kutty R; Rosengren A; Mohan V; Avezum A; Yusuf R; Szuba A; Rangarajan S; Chow C; Yusuf S; Lancet Public Health; 2017 Sep; 2(9):e411-e419. PubMed ID: 29253412 [TBL] [Abstract][Full Text] [Related]
14. Potent analgesics are more expensive for patients in developing countries: a comparative study. De Lima L; Sweeney C; Palmer JL; Bruera E J Pain Palliat Care Pharmacother; 2004; 18(1):59-70. PubMed ID: 15148009 [TBL] [Abstract][Full Text] [Related]
15. Medication Use for Cardiovascular Disease Prevention in 40 Low- and Middle-Income Countries. Zhu JZ; Manne-Goehler J; Agarwal A; Bahendeka SK; Damasceno A; Marcus ME; Saeedi Moghaddam S; Vollmer S; Huffman MD; Flood D; J Am Coll Cardiol; 2023 Feb; 81(6):620-622. PubMed ID: 36754520 [TBL] [Abstract][Full Text] [Related]
17. Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones. Shantsila A; Lip GY Int J Clin Pract; 2010 Jan; 64(2):138-40. PubMed ID: 20089004 [No Abstract] [Full Text] [Related]
18. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lim SS; Gaziano TA; Gakidou E; Reddy KS; Farzadfar F; Lozano R; Rodgers A Lancet; 2007 Dec; 370(9604):2054-62. PubMed ID: 18063025 [TBL] [Abstract][Full Text] [Related]
19. Effects of essential medicines on cardiovascular products available for the market in Thailand. Burapadaja S; Kawasaki N; Charumanee S; Ogata F Health Policy; 2007 Nov; 84(1):67-74. PubMed ID: 17374418 [TBL] [Abstract][Full Text] [Related]
20. [How we treat patients with cardiovascular diseases in real clinical practice]. Belenkov IuN; Mareev VIu Ter Arkh; 2003; 75(8):5-11. PubMed ID: 14520842 [No Abstract] [Full Text] [Related] [Next] [New Search]